RecruitingPhase 3NCT06758401
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Sigvotatug Vedotin(drug)
- Enrollment
- 714 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center, Fullerton, California, United States
- Providence St. Jude Medical Center, Fullerton, California, United States
- St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test), Fullerton, California, United States
- Intermountain Health Cancer Center Lutheran Hospital, Golden, Colorado, United States
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction, Colorado, United States
- Intermountain Health St. Mary's Regional Hospital, Grand Junction, Colorado, United States
- Intermountain Health, Grand Junction, Colorado, United States
- Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States
- Washington DC Veterans Affairs Medical Center, Washington D.C., District of Columbia, United States
- Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
- BRCR Global, Plantation, Florida, United States
- Endeavor Health, Elmhurst, Illinois, United States
- Hope and Healing Cancer Services, Hinsdale, Illinois, United States
- Endeavor Health, Naperville, Illinois, United States
- Hope and Healing Cancer Services, New Lenox, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06758401 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →